Brincidofovir is an antiviral prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of smallpox in adults and children, including newborn infants. (Smallpox is a disease caused by the variola virus, a member of a group of viruses called orthopoxviruses. Since 1980, smallpox has been considered eradicated worldwide.). It is grouped under the following drug class(es): DNA polymerase inhibitors and Nucleotides. Its therapeutic use is listed as antivirals. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include brincidofovirum and Tembexa. Its PubChem CID is 483477.
Brincidofovir
| CAS No | 444805-28-1 |
|---|---|
| Molecular Formula | C27H52N3O7P |
| Molecular Weight | 561.70 g/mol |
| Synonyms | [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
S. Food and Drug Administration (FDA) for the treatment of smallpox in adults and children, including newborn infants. (Smallpox is a disease caused by the variola virus, a member of a group of viruses called orthopoxviruses.
The listed CAS number is 444805-28-1.
The listed molecular formula is C27H52N3O7P.
The listed molecular weight is 561.70 g/mol.
[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid.
The source lists brincidofovirum and Tembexa.